Hytrin is a brand name of terazosin, approved by the FDA in the following formulation(s):
HYTRIN (terazosin hydrochloride - capsule; oral)
Manufacturer: ABBOTT
Approval date: December 14, 1994
Strength(s): EQ 10MG BASE [AB], EQ 1MG BASE [AB], EQ 2MG BASE [RLD][AB], EQ 5MG BASE [AB]
HYTRIN (terazosin hydrochloride - tablet; oral)
Manufacturer: ABBOTT
Approval date: August 7, 1987
Strength(s): EQ 10MG BASE, EQ 1MG BASE, EQ 2MG BASE [RLD], EQ 5MG BASE
Has a generic version of Hytrin been approved?
A generic version of Hytrin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Hytrin and have been approved by the FDA:
terazosin hydrochloride capsule; oral
Manufacturer: APOTEX
Approval date: April 12, 2001
Strength(s): EQ 10MG BASE [AB], EQ 1MG BASE [AB], EQ 2MG BASE [AB], EQ 5MG BASE [AB]
Manufacturer: IVAX SUB TEVA PHARMS
Approval date: January 30, 2001
Strength(s): EQ 10MG BASE [AB], EQ 1MG BASE [AB], EQ 2MG BASE [AB], EQ 5MG BASE [AB]
Manufacturer: JUBILANT CADISTA
Approval date: December 20, 2004
Strength(s): EQ 10MG BASE [AB], EQ 1MG BASE [AB], EQ 2MG BASE [AB], EQ 5MG BASE [AB]
Manufacturer: MYLAN
Approval date: February 11, 2000
Strength(s): EQ 10MG BASE [AB], EQ 1MG BASE [AB], EQ 2MG BASE [AB], EQ 5MG BASE [AB]
Manufacturer: RANBAXY
Approval date: August 22, 2002
Strength(s): EQ 10MG BASE [AB], EQ 1MG BASE [AB], EQ 2MG BASE [AB], EQ 5MG BASE [AB]
Manufacturer: SANDOZ
Approval date: March 30, 1998
Strength(s): EQ 10MG BASE [AB], EQ 1MG BASE [AB], EQ 2MG BASE [AB], EQ 5MG BASE [AB]
Note: No generic formulation of the following product is available.
- terazosin hydrochloride - tablet; oral
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Hytrin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Terazosin polymorph and pharmaceutical composition
Patent 5,294,615
Issued: March 15, 1994
Inventor(s): Meyer; Glenn A. & Bauer; John F.
Assignee(s): Abbott Laboratories
A novel anhydrous crystalline polymorph of 1-(4-amino-6,7-dimethoxy- 2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine monohydrochloride is disclosed, together with pharmaceutical formulations containing the compound. The novel polymorph exhibits a diminished food effect when administered to human subjects.Patent expiration dates:
- April 29, 2013✓
- April 29, 2013✓
- April 29, 2013
Terazosin monohydrochloride and processes and intermediate for its production
Patent 5,412,095
Issued: May 2, 1995
Inventor(s): Morley; James A. & Bauer; John F. & Patel; Ramesh F. & Henry; Rodger E. & Spanton; Stephen G.
Assignee(s): Abbott Laboratories
The present invention provides a non-solvated crystalline polymorph of terazosin monohydrochloride designated Form III and methods for its preparation. Also disclosed is terazosin monohydrochloride methanolate and processes for its production as well as processes for its conversion to other crystalline forms of terazosin monohydrochloride.Patent expiration dates:
- April 29, 2013
- April 29, 2013
See also...
- Hytrin Consumer Information (Drugs.com)
- Hytrin Consumer Information (Wolters Kluwer)
- Hytrin Consumer Information (Cerner Multum)
- Hytrin Advanced Consumer Information (Micromedex)
- Hytrin AHFS DI Monographs (ASHP)
- Terazosin Consumer Information (Drugs.com)
- Terazosin Consumer Information (Wolters Kluwer)
- Terazosin Consumer Information (Cerner Multum)
- Terazosin Advanced Consumer Information (Micromedex)
- Terazosin Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment